Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02726750 · ClinicalTrials.gov registry record
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
A clinical trial of Monoclonal Gammopathy of Undetermined Significance and Smoldering Plasma Cell Myeloma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT02726750: Recruiting study of Monoclonal Gammopathy of Undetermined Significance and Smoldering Plasma Cell Myeloma, sponsored by M.D. Anderson Cancer Center.
NCT02726750 is a study of Monoclonal Gammopathy of Undetermined Significance and Smoldering Plasma Cell Myeloma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 200 participants, below the 662-participant average among 11 other Monoclonal Gammopathy of Undetermined Significance trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02726750, a study of Monoclonal Gammopathy of Undetermined Significance and Smoldering Plasma Cell Myeloma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may help researchers to validate clinical and genomic predictors for future use in clinical practice.
Primary Outcome
Kaplan-Meier method will be used to estimate time to MM progression. Log-rank test will be used to evaluate the difference in rate of progression between/among patient groups.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-12-14 |
| Est. Completion | 2026-04-30 |
What NCT02726750 shows while recruiting
NCT02726750 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 662-participant average among 11 other Monoclonal Gammopathy of Undetermined Significance trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Monoclonal Gammopathy of Undetermined Significance appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT02726750 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02726750 about?
NCT02726750 is a clinical study titled "Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma". The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying mar...
What is the current status of trial NCT02726750?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2015-12-14. Estimated completion is 2026-04-30.
What conditions does trial NCT02726750 study?
This clinical trial studies the following conditions: Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma.
What interventions are being tested in trial NCT02726750?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02726750?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02726750 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Monoclonal Gammopathy of Undetermined Significance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02726750's enrollment target sits among peer trials
200 5th of 11 higher than 5 of 11 other Monoclonal Gammopathy of Undetermined Significance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Monoclonal Gammopathy of Undetermined Significance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Sleep Apnea in Patients With MGUS and MM
RECRUITING
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
RECRUITING · Phase 2
-
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
RECRUITING · NA
-
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI